Genentech to operate at near-capacity to satisfy clamor for its drugs

06/27/2005 | Reuters

Demand for Genentech's highly successful drugs, such as Avastin, has caused the company to operate at near-capacity and has led the company to cancel a separate deal with Amgen to manufacture that firm's products. Genentech's senior vice president of product operations said he does not like operating at capacity "for an extended period of time," but the company's plan is to do that for some time, while making additional operational capacity available.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC